{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Acute optic neuritis/myelitis within 2 weeks Speeds neurological recovery No systemic infection or contraindication evident\n\n*   **Treatment:** Proton pump inhibitor for gastroprotection\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** High-dose corticosteroid use Prevention of steroid-related gastritis/ulcer\n\n*   **Treatment:** Venous thromboembolism prophylaxis (LMWH and mechanical)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Reduced mobility from myelopathy Prevent hospital-acquired VTE\n\n*   **Treatment:** Physiotherapy and gait/balance rehabilitation\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Improve mobility and reduce falls risk Address spasticity and proprioceptive deficit\n\n*   **Treatment:** Plasma exchange (5\u20137 sessions)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Reserve for poor response to steroids or strong suspicion of NMOSD/MOGAD Initiate within 7\u201314 days if inadequate improvement\n\n*   **Treatment:** Disease-modifying therapy for MS (e.g., ocrelizumab/natalizumab per JCV status)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Start only after diagnostic confirmation and risk stratification Requires discussion of options and monitoring plan\n\n*   **Treatment:** Rituximab (if NMOSD confirmed)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Indicated for AQP4-IgG NMOSD prevention Begin after antibody confirmation and vaccination review\n\n*   **Treatment:** Urgent neurosurgical decompression\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Only if MRI shows compressive thoracic cord lesion Surgical indication contingent on imaging\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Start Now\", \"reasons\": [\"Acute optic neuritis/myelitis within 2 weeks\", \"Speeds neurological recovery\", \"No systemic infection or contraindication evident\"]}, {\"treatment\": \"Proton pump inhibitor for gastroprotection\", \"timing\": \"Start Now\", \"reasons\": [\"High-dose corticosteroid use\", \"Prevention of steroid-related gastritis/ulcer\"]}, {\"treatment\": \"Venous thromboembolism prophylaxis (LMWH and mechanical)\", \"timing\": \"Start Now\", \"reasons\": [\"Reduced mobility from myelopathy\", \"Prevent hospital-acquired VTE\"]}, {\"treatment\": \"Physiotherapy and gait/balance rehabilitation\", \"timing\": \"Start Now\", \"reasons\": [\"Improve mobility and reduce falls risk\", \"Address spasticity and proprioceptive deficit\"]}, {\"treatment\": \"Plasma exchange (5\\u20137 sessions)\", \"timing\": \"Delay\", \"reasons\": [\"Reserve for poor response to steroids or strong suspicion of NMOSD/MOGAD\", \"Initiate within 7\\u201314 days if inadequate improvement\"]}, {\"treatment\": \"Disease-modifying therapy for MS (e.g., ocrelizumab/natalizumab per JCV status)\", \"timing\": \"Delay\", \"reasons\": [\"Start only after diagnostic confirmation and risk stratification\", \"Requires discussion of options and monitoring plan\"]}, {\"treatment\": \"Rituximab (if NMOSD confirmed)\", \"timing\": \"Delay\", \"reasons\": [\"Indicated for AQP4-IgG NMOSD prevention\", \"Begin after antibody confirmation and vaccination review\"]}, {\"treatment\": \"Urgent neurosurgical decompression\", \"timing\": \"Delay\", \"reasons\": [\"Only if MRI shows compressive thoracic cord lesion\", \"Surgical indication contingent on imaging\"]}]"
}